Integra LifeSciences Holdings Corporation (IART)

IART Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	67.74	180.55	169.08	133.89	50.2
Depreciation & Amortization	125.7	121.12	123.67	118.99	114.52
Share-Based Compensation	20.14	27.73	36.21	19.59	21.26
Other Operating Activities	-73.63	-64.92	-16.53	-68.64	45.46
Operating Cash Flow	139.96	264.47	312.43	203.83	231.43
Operating Cash Flow Growth	-47.08%	-15.35%	53.28%	-11.93%	15.90%
Capital Expenditures	-66.87	-31.2	-48.02	-35.23	-69.5
Acquisitions	0	-32.29	-113.5	-25	-95.5
Change in Investments	-27.31	4.91	0.08	-7.84	2.34
Investing Cash Flow	-94.18	-58.58	-161.44	-68.07	-162.67
Share Issuance / Repurchase	-270.68	-119.54	6.82	-94.77	6.95
Debt Issued / Paid	46.62	-107.8	-100.25	281.15	-9.2
Other Financing Activities	-5.86	-24.62	-4.8	-64.76	-6.51
Financing Cash Flow	-229.93	-251.95	-98.23	121.63	-8.77
Exchange Rate Effect	3.89	-10.72	-9.48	13.87	0.07
Net Cash Flow	-180.26	-56.79	43.28	271.26	60.07
Free Cash Flow	73.09	233.27	264.41	168.6	161.93
Free Cash Flow Growth	-68.67%	-11.78%	56.83%	4.12%	32.34%
Free Cash Flow Margin	4.74%	14.98%	17.14%	12.29%	10.67%
Free Cash Flow Per Share	0.91	2.81	3.12	1.99	1.89

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).